更多
自定内容
更多
———————————————————————————————————————————                                          ———————————————————————————————————————————                  
自定内容
更多

新闻资讯

News

图片
更多
自定内容
更多
{
导航菜单
更多
自定内容
更多
遇见。花
自定内容
更多
}
文章分类
更多
更多
文章正文
更多
百奥赛图邀您共同探讨—生物医药研发的未来方向
作者:    发布于:2019-07-10 11:58   

本次大会由Biocytogen和AcroBiosystem联合主办,围绕生物医药以及抗体药物的发现与发展,致力于为生物医药产业做出更多的贡献。

会议于美国时间2019年6月13日下午1-6点在___召开,届时欢迎大家莅临参会。

Free to attend, light dinner will be provided. Join Biocytogen and AcroBiosystem to learn more about the cutting-edge technologies and latest research in biologic drug development. The symposium is co-organized by Biocytogenand AcroBiosystem, focusing mainly on therapeutic antibody and biologic drug discovery and development.
Theme:Future of Biologic Drug Discovery and Development

Time:June 13th, 1:00 PM - 6:00 PM

Location:Residence Inn Boston Cambridge, 120 Broadway, Six Cambridge Center, Cambridge, MA

Confirmed Speakers

Chun-Nan Chen

CEO and CSO, Single Cell Technology

Qingcong Lin

CEO, Biocytogen Boston Corp

Stephen Gillies

CSO, LinkedUp Bioscience Inc

Johanna Lahdenranta

Director of In Vivo Pharmacology, Bicycle Therapeutics

Xiaodong Li

Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP

Agenda

1:00 PM - 1:20 PM

Registration

1:20 PM - 1:30 PM

Welcome Remark

1:30 PM - 2:00 PM

Introducing AbTheneum, A High Throughput and Data-rich Antibody Discovery Platform by Single Cell Technology

Chun-Nan Chen, CEO and CSO, Single Cell Technology

Named after an institution of great knowledge, AbTheneum™ is Single Cell Technology’s antibody discovery platform. Deploying AbTheneum™, we screen thousands of antibody-secreting cells for binding characteristics and sequence all the cells to return native heavy and light chain sequence pairs correlated with the binding activity for each antibody from single cells. AbTheneum™ screening assay is flexible and can be customized for any target to find cross-reactivity, epitope specificity, and more. Case studies will be shown for anti-BCMA and anti-FOLR1 antibody leads discovered using AbTheneum™ and their validation data. The discovery of these high-quality and therapeutically relevant antibody candidates highlights the power of AbTheneum™.

2:00 PM - 2:30 PM

Accelerating Therapeutic Antibody Candidate Discovery using Biocytogen Humanized Mouse Models

Qingcong Lin, CEO, Biocytogen Boston Corp

The traditional therapeutic antibody discovery is a lengthy, multi-staged process from hit generation, lead screening, optimization to candidate selection. Depending on surrogate antibodies for efficacy tests in animal models has significantly constrained the therapeutic antibody discovery. This presentation will discuss three approaches to expedite the process. First, Biocytogen has generated thirty+ IO checkpoint humanized GEMM, enabling direct testing of anti-human antibodies in mice without depending on mouse cross-reactive antibody candidates. We have also created human CD3 knock-in mice for testing T cell-engaging bispecific antibodies. Second, our proprietary immunodeficient B-NDG and series of B-NDG variant mice are excellent host for engraftment of human PBMC and CD34+ hematopoietic stem cells and allow testing anti-human antibody candidate efficacy and safety. Finally, we have generated RenMab mice, by introducing the complete human heavy chain and light chain V(D)J regions to replace the mouse counterpart loci. A case study, where we considerably shortened the hit to lead process by conducting high-throughput in vivo efficacy-based lead identification using our humanized mice will also be presente_________>2:30 PM - 3:00 PM

Humanized Mice for Studies of Immunocytokine Mono and Combi-therapies

Stephen Gillies, CSO, LinkedUp Bioscience Inc

Antibody-cytokine fusion proteins (immunocytokines or IC) target the tumor microenvironment where they stimulate a cascade of immune responses based on their interaction with resident tumor, stroma and infiltrating lymphocytes, macrophage and myeloid cells. The goal is to overcome this immune suppressive environment. Due to species specificity of cytokine and cytokine receptor interactions, the best way is to use murine cytokines in syngeneic tumor models or to use humanized NOG mice with the all human antibody and cytokine molecules being developed as potential drugs. Many years ago, in collaboration with Jackson Labs and the University of Tuebingen, we developed models in which CD34+ human hematopoietic stem cells were adoptively transferred into irradiated NOG mice and given weekly doses of long-lasting IL7 (Fc-IL7). This resulted in mice with high numbers of human B, NK and T cells that quickly develop diverse TCR repertoires and have since been shown to be highly functional in IC-induced anti-tumor efficacy. One such IC, NHS-IL12, contains two molecules of species-specific human IL12 and targets DNA that is released into the necrotic regions of all solid tumors, independent of species. Studies include combination therapies with local radiation or with other cytokines leading to some surprising results.

3:00 PM - 3:30 PM

Coffee Break and Networking

3:30 PM - 4:00 PM

Activation of CD137 Using Multivalent and Tumor Targeted Bicyclic Peptides

Johanna Lahdenranta, Director of In Vivo Pharmacology, Bicycle Therapeutics

4:00 PM - 4:30 PM

Patent Portfolio Development for Biologic Products

Xiaodong Li,Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP

Biological products are typically protected by patent portfolios comprising a number of patents. Using specific products a____amples, Xiaodong will discuss how to use different types of patent filings and claims to provide layered protection for biological products and how to maximize their patent protection. He will share hi____perience on how to identify inventions at various development and commercial stages and how to protect them accordingly.

4:30 PM – 6:00 PM

Dinner Reception (Light dinner will be provided)

To register for the symposium, please or go to"register"

全屏背景
更多
自定内容
更多

Copyright © 2018 澳门新濠天地娱乐场官网澳门新濠天地娱乐场官网-澳门新濠天地娱乐网址 All Rights Reserved

您的网站名称 未经许可 严禁复制 

 备案号:

自定内容
更多

品牌精神


某某花卉行业新品牌,引领 花卉行业新品质

自定内容
更多

运输包装


由于是鲜花类物品,包装 前会用保鲜剂后礼盒

自定内容
更多

退订服务


网上订购货物,一律支持 7天无理由退货

自定内容
更多

邮资服务


网上下单,邮资服务支持 全场满199元包邮

图片
更多
图片
更多
图片
更多
图片
更多
图片
更多
更多